Literature DB >> 24692588

Should publications on mesenchymal stem/progenitor cells include in-process data on the preparation of the cells?

Roxanne L Reger1, Darwin J Prockop.   

Abstract

There has been great interest in research and clinical trials with the adult stem/progenitor cells referred to as mesenchymal stem/stromal cells (MSCs). However, there are no definitive markers for the cells and no assays that would reflect the therapeutic efficacy of the cells in vivo. There are in effect no adequate release criteria that define the quality or efficacy of the cells. The problems are compounded by the fact that a variety of different protocols has been used to isolate the cells and expand them in culture. The result is that many publications have used MSCs with different properties, frequently without the investigators being aware of the differences. As a partial solution to these problems, we have devised a simple table to record in-process data on the preparation of MSCs. We suggest that comparisons of data generated by different laboratories would be facilitated if similar in-process data, probably as supplemental materials, were included in publications using MSCs.

Keywords:  Criteria; Heterogeneity; Plasticity

Mesh:

Year:  2014        PMID: 24692588      PMCID: PMC4006492          DOI: 10.5966/sctm.2013-0203

Source DB:  PubMed          Journal:  Stem Cells Transl Med        ISSN: 2157-6564            Impact factor:   6.940


  30 in total

1.  Rat marrow stromal cells are more sensitive to plating density and expand more rapidly from single-cell-derived colonies than human marrow stromal cells.

Authors:  E H Javazon; D C Colter; E J Schwarz; D J Prockop
Journal:  Stem Cells       Date:  2001       Impact factor: 6.277

2.  Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury.

Authors:  Mohammad Naimul Islam; Shonit R Das; Memet T Emin; Michelle Wei; Li Sun; Kristin Westphalen; David J Rowlands; Sadiqa K Quadri; Sunita Bhattacharya; Jahar Bhattacharya
Journal:  Nat Med       Date:  2012-04-15       Impact factor: 53.440

3.  Sox11 is expressed in early progenitor human multipotent stromal cells and decreases with extensive expansion of the cells.

Authors:  Benjamin L Larson; Joni Ylostalo; Ryang H Lee; Carl Gregory; Darwin J Prockop
Journal:  Tissue Eng Part A       Date:  2010-07-13       Impact factor: 3.845

4.  Mitochondrial transfer between cells can rescue aerobic respiration.

Authors:  Jeffrey L Spees; Scott D Olson; Mandolin J Whitney; Darwin J Prockop
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

Review 5.  Heterogeneity of mesenchymal stromal cell preparations.

Authors:  A D Ho; W Wagner; W Franke
Journal:  Cytotherapy       Date:  2008       Impact factor: 5.414

6.  Freezing harvested hMSCs and recovery of hMSCs from frozen vials for subsequent expansion, analysis, and experimentation.

Authors:  Roxanne L Reger; Margaret R Wolfe
Journal:  Methods Mol Biol       Date:  2008

Review 7.  Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease.

Authors:  Sudhir H Ranganath; Oren Levy; Maneesha S Inamdar; Jeffrey M Karp
Journal:  Cell Stem Cell       Date:  2012-03-02       Impact factor: 24.633

8.  Activation of human mesenchymal stem cells impacts their therapeutic abilities in lung injury by increasing interleukin (IL)-10 and IL-1RN levels.

Authors:  Martha L Bustos; Luai Huleihel; Ernest M Meyer; Albert D Donnenberg; Vera S Donnenberg; Joseph D Sciurba; Lyle Mroz; Bryan J McVerry; Bryon M Ellis; Naftali Kaminski; Mauricio Rojas
Journal:  Stem Cells Transl Med       Date:  2013-10-02       Impact factor: 6.940

9.  Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT).

Authors:  Philippe Bourin; Bruce A Bunnell; Louis Casteilla; Massimo Dominici; Adam J Katz; Keith L March; Heinz Redl; J Peter Rubin; Kotaro Yoshimura; Jeffrey M Gimble
Journal:  Cytotherapy       Date:  2013-04-06       Impact factor: 5.414

10.  Genome-wide map of quantified epigenetic changes during in vitro chondrogenic differentiation of primary human mesenchymal stem cells.

Authors:  Sarah R Herlofsen; Jan Christian Bryne; Torill Høiby; Li Wang; Robbyn Issner; Xiaolan Zhang; Michael J Coyne; Patrick Boyle; Hongcang Gu; Leonardo A Meza-Zepeda; Philippe Collas; Tarjei S Mikkelsen; Jan E Brinchmann
Journal:  BMC Genomics       Date:  2013-02-15       Impact factor: 3.969

View more
  10 in total

Review 1.  Research using Mesenchymal Stem/Stromal Cells: quality metric towards developing a reference material.

Authors:  Vivek Tanavde; Candida Vaz; Mahendra S Rao; Mohan C Vemuri; Radhika R Pochampally
Journal:  Cytotherapy       Date:  2015-09       Impact factor: 5.414

2.  Study of Bone Marrow and Embryonic Stem Cell-Derived Human Mesenchymal Stem Cells for Treatment of Escherichia coli Endotoxin-Induced Acute Lung Injury in Mice.

Authors:  Qi Hao; Ying-Gang Zhu; Antoine Monsel; Stephane Gennai; Travis Lee; Fengyun Xu; Jae-Woo Lee
Journal:  Stem Cells Transl Med       Date:  2015-05-21       Impact factor: 6.940

Review 3.  Biological Therapies in Regenerative Sports Medicine.

Authors:  Isabel Andia; Nicola Maffulli
Journal:  Sports Med       Date:  2017-05       Impact factor: 11.136

Review 4.  The exciting prospects of new therapies with mesenchymal stromal cells.

Authors:  Darwin J Prockop
Journal:  Cytotherapy       Date:  2016-10-18       Impact factor: 5.414

Review 5.  Potential advantages of acute kidney injury management by mesenchymal stem cells.

Authors:  Francesca Bianchi; Elisa Sala; Chiara Donadei; Irene Capelli; Gaetano La Manna
Journal:  World J Stem Cells       Date:  2014-11-26       Impact factor: 5.326

6.  Intraperitoneally infused human mesenchymal stem cells form aggregates with mouse immune cells and attach to peritoneal organs.

Authors:  Nikolay Bazhanov; Joni H Ylostalo; Thomas J Bartosh; April Tiblow; Arezoo Mohammadipoor; Andrea Foskett; Darwin J Prockop
Journal:  Stem Cell Res Ther       Date:  2016-02-10       Impact factor: 6.832

7.  ALCAM (CD166) as a gene expression marker for human mesenchymal stromal cell characterisation.

Authors:  Bas Brinkhof; Bo Zhang; Zhanfeng Cui; Hua Ye; Hui Wang
Journal:  Gene X       Date:  2020-03-14

8.  Trends in mesenchymal stem cell clinical trials 2004-2018: Is efficacy optimal in a narrow dose range?

Authors:  Maciej Kabat; Ivan Bobkov; Suneel Kumar; Martin Grumet
Journal:  Stem Cells Transl Med       Date:  2019-12-05       Impact factor: 6.940

Review 9.  Are clinical trials with mesenchymal stem/progenitor cells too far ahead of the science? Lessons from experimental hematology.

Authors:  Darwin J Prockop; Susan E Prockop; Ivan Bertoncello
Journal:  Stem Cells       Date:  2014-12       Impact factor: 6.277

10.  Mesenchymal stromal cells mediated delivery of photoactive nanoparticles inhibits osteosarcoma growth in vitro and in a murine in vivo ectopic model.

Authors:  Stefania Lenna; Chiara Bellotti; Serena Duchi; Elisa Martella; Marta Columbaro; Barbara Dozza; Marco Ballestri; Andrea Guerrini; Giovanna Sotgiu; Tommaso Frisoni; Luca Cevolani; Greta Varchi; Mauro Ferrari; Davide Maria Donati; Enrico Lucarelli
Journal:  J Exp Clin Cancer Res       Date:  2020-02-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.